Hypersensitivity pneumonitis: Lessons from a randomized controlled trial in children.

Area of Science:

• Pediatric Pulmonology
• Interstitial Lung Diseases
• Clinical Trials

Background:

• Hypersensitivity pneumonitis (HP) in children is a severe interstitial lung disease.
• Lack of evidence-based guidelines exists for pediatric HP treatment.
• The efficacy of systemic glucocorticoid therapy in children with HP is uncertain.

Purpose of the Study:

• To assess treatment outcomes in pediatric HP after 6 months.
• To compare 3 months of oral prednisolone versus placebo in children with HP.
• To evaluate the safety and efficacy of glucocorticoid treatment in pediatric HP.

Main Methods:

• A randomized, double-blind, placebo-controlled, multi-center, phase II trial.
• Inclusion of pediatric patients diagnosed with HP.
• Comparison of oral prednisolone treatment against a placebo group.

Main Results:

• The study was terminated prematurely after 1.5 years with only four participants.
• Two children receiving prednisolone did not achieve the target Forced Vital Capacity (FVC) response.
• One child on placebo and one on prednisolone recovered to normal lung function; all steroid-treated children experienced side effects.

Conclusions:

• The premature termination highlights the challenges in rare pediatric disease research.
• There is an urgent need for evidence-based treatment protocols for pediatric HP.
• Consideration should be given to including pediatric patients in adult HP studies to address unanswered questions.